<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A626A11E-2224-4AB7-9B84-712CE1E0A709"><gtr:id>A626A11E-2224-4AB7-9B84-712CE1E0A709</gtr:id><gtr:name>Tangent Reprofiling Limited</gtr:name><gtr:address><gtr:line1>100 FETTER LANE</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>EC4A 1BN</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A626A11E-2224-4AB7-9B84-712CE1E0A709" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A626A11E-2224-4AB7-9B84-712CE1E0A709</gtr:id><gtr:name>Tangent Reprofiling Limited</gtr:name><gtr:address><gtr:line1>100 FETTER LANE</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>EC4A 1BN</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>180117.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710081"><gtr:id>B7035365-9BA3-4F54-811D-08EE2345FE5C</gtr:id><gtr:title>Tangent Reprofiling - Combination therapies for hormone-dependent cancers. Utilising an innovative therapeutic strategy of drugs and nutritional supplements. Treating Prostate (and Ovarian, Breast and Endometrial) cancers beyond castration resistance.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710081</gtr:grantReference><gtr:abstractText>Some cancerous tumors require, or grow faster in the presence of, steroid hormones such as estrogen or testosterone. These cancers can be treated by chemotherapy drugs to prevent the tumor using hormones found naturally in the body. Many of these drugs work by blocking the receptors for the hormone on the outside edges of the tumor, starving the tumor by preventing it from recognizing the hormone. However, many hormone-dependant tumors develop resistance to these drugs by learning to make the hormones internally.
We used our proprietary technology to study drugs that are currently used in non-cancer
diseases. One drug was identified as being capable of preventing internal hormone production by tumors. This drug is already in clinical use for an alternative disease which requires long term use, so the safety and side effects are already well characterized across a broad population of patients. We propose combining this drug with current chemotherapy regimes to attack the tumor from within while maintaining the starvation procedure described above.
We already have data to demonstrate a reduction in growth of prostate cancer cells with the drug in vitro, however, we now need to expand this to look at additional combinations of drugs; to look at additional cancer cell types; and to test the final drug combinations in animal models.
As well as combining our drug with current chemotherapies, we will test it in combination with omega-3 fatty acids. These are popular nutritional supplements, and have been proposed to have therapeutic effect in some cancers. This supplement should work in concert with our drug to provide additional benefit. There are several forms of omega-3 fatty acids, so we need to identify the best and then look for the ideal ratio of our drug and the supplement.
We believe this offers an exciting opportunity to prolong successful treatment of a range of common cancers including prostate, endometrial, breast and ovarian cancer.</gtr:abstractText><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710081</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>